Logo image of ACIU

AC IMMUNE SA (ACIU) Stock Price, Quote, News and Overview

NASDAQ:ACIU - Nasdaq - CH0329023102 - Common Stock - Currency: USD

2.65  -0.01 (-0.38%)

ACIU Quote, Performance and Key Statistics

AC IMMUNE SA

NASDAQ:ACIU (2/21/2025, 8:00:00 PM)

2.65

-0.01 (-0.38%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.98
52 Week Low2.25
Market Cap262.19M
Shares98.94M
Float61.17M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-12 2025-03-12/amc
IPO09-23 2016-09-23


ACIU short term performance overview.The bars show the price performance of ACIU in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ACIU long term performance overview.The bars show the price performance of ACIU in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30

The current stock price of ACIU is 2.65 USD. In the past month the price decreased by -1.85%. In the past year, price decreased by -22.97%.

AC IMMUNE SA / ACIU Daily stock chart

ACIU Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ACIU

Company Profile

ACIU logo image AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Company Info

AC IMMUNE SA

EPFL Innovation Park, Building B

Lausanne VAUD 1015 CH

CEO: Andrea Pfeifer

Employees: 147

Company Website: https://www.acimmune.com/

Investor Relations: https://ir.acimmune.com/

Phone: 41213459121

AC IMMUNE SA / ACIU FAQ

What is the stock price of AC IMMUNE SA today?

The current stock price of ACIU is 2.65 USD. The price decreased by -0.38% in the last trading session.


What is the ticker symbol for AC IMMUNE SA stock?

The exchange symbol of AC IMMUNE SA is ACIU and it is listed on the Nasdaq exchange.


On which exchange is ACIU stock listed?

ACIU stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AC IMMUNE SA stock?

10 analysts have analysed ACIU and the average price target is 10.2 USD. This implies a price increase of 284.91% is expected in the next year compared to the current price of 2.65. Check the AC IMMUNE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AC IMMUNE SA worth?

AC IMMUNE SA (ACIU) has a market capitalization of 262.19M USD. This makes ACIU a Micro Cap stock.


How many employees does AC IMMUNE SA have?

AC IMMUNE SA (ACIU) currently has 147 employees.


What are the support and resistance levels for AC IMMUNE SA (ACIU) stock?

AC IMMUNE SA (ACIU) has a resistance level at 2.66. Check the full technical report for a detailed analysis of ACIU support and resistance levels.


Is AC IMMUNE SA (ACIU) expected to grow?

The Revenue of AC IMMUNE SA (ACIU) is expected to grow by 80.09% in the next year. Check the estimates tab for more information on the ACIU EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AC IMMUNE SA (ACIU) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AC IMMUNE SA (ACIU) stock pay dividends?

ACIU does not pay a dividend.


When does AC IMMUNE SA (ACIU) report earnings?

AC IMMUNE SA (ACIU) will report earnings on 2025-03-12, after the market close.


What is the Price/Earnings (PE) ratio of AC IMMUNE SA (ACIU)?

AC IMMUNE SA (ACIU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.46).


What is the Short Interest ratio of AC IMMUNE SA (ACIU) stock?

The outstanding short interest for AC IMMUNE SA (ACIU) is 1.73% of its float. Check the ownership tab for more information on the ACIU short interest.


ACIU Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ACIU Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ACIU. ACIU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACIU Financial Highlights

Over the last trailing twelve months ACIU reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS increased by 50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -16.32%
ROE -30.62%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%127.78%
Sales Q2Q%N/A
EPS 1Y (TTM)50%
Revenue 1Y (TTM)279.51%

ACIU Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to ACIU. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 14.55% and a revenue growth 80.09% for ACIU


Ownership
Inst Owners28.02%
Ins Owners3.06%
Short Float %1.73%
Short Ratio6.49
Analysts
Analysts88
Price Target10.2 (284.91%)
EPS Next Y14.55%
Revenue Next Year80.09%